Author/Authors :
Wang, WG Jilin University - First Bethune Hospital - Urinary Diseases Diagnosis Treatment Center, China , Wang, YT Jilin University - First Bethune Hospital - Urinary Diseases Diagnosis Treatment Center, China , Zhou, HL Jilin University - First Bethune Hospital - Urinary Diseases Diagnosis Treatment Center, China , Li, P Jilin University - China-Japan Union Hospital - Department of Rheumatology, China , Wang, G Jilin University - First Bethune Hospital - Urinary Diseases Diagnosis Treatment Center, China , Gao, BS Jilin University - First Bethune Hospital - Urinary Diseases Diagnosis Treatment Center, China , Fu, YW Jilin University - First Bethune Hospital - Urinary Diseases Diagnosis Treatment Center, China
Abstract :
Rifampicin is a semisynthetic derivative of rifamycin B and inhibits the growth of a variety of bacteria. Rifampicin causes an increase in corticosteroid clearance, and a decrease in the blood concentrations of calcineurin inhibitors by inducing Cytochrome P450 3A4 in the liver. It is generally acknowledged that a substantial increase in the dosage of calcineurin inhibitors is required to achieve the efficacious target concentrations and avoid graft rejection. We report a case of patient who received a living-related donor renal transplant with stable renal function during the rifampicin based anti-tuberculosis treatment, even the blood concentration of tacrolimus (FK506) decreased. Interestingly, acute rejection was observed at the end of anti-tuberculosis treatment, even the blood concentration of FK506 was reduced to target level.
Keywords :
Rifampicin , Tuberculosis , Renal transplant , Immunosuppression.
